Trial Profile
An open label, multicenter Post Marketing Surveillance Study in India to assess safety and efficacy of Intramuscular administration of stempeucel in patients with critical limb ischemia due to Buerger's disease
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 13 Nov 2019
Price :
$35
*
At a glance
- Drugs Mesenchymal stem cell therapy (Primary)
- Indications Chronic limb-threatening ischemia; Peripheral ischaemia
- Focus Adverse reactions; Therapeutic Use
- Sponsors Stempeutics
- 11 Sep 2018 Status changed from not yet recruiting to recruiting.
- 25 Jun 2018 New trial record